Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Current Deferred Revenue (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Current Deferred Revenue for 6 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue changed N/A to $4.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $4.2 million for FY2025, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2025 was $4.2 million at Crescent Biopharma, up from $74072.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $4.2 million in Q4 2025, with the low at $4.2 million in Q4 2025.